CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Ixazomib Citrate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02619682
NCT02619682Phase 2Completed
CompareCT.gov

Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy After Autologous Transplant for Treating Multiple Myeloma

Fred Hutchinson Cancer Center·interventional·Posted Dec 2, 2015·Updated Jan 8, 2026

In Brief

A Phase 2 clinical trial evaluating Ixazomib Citrate, Laboratory Biomarker Analysis, and 1 other intervention for Plasma Cell Myeloma and Transplant-Related Carcinoma. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This phase II trial studies the safety of alternating ixazomib citrate and lenalidomide as treatment to help keep cancer from coming back after stem cell transplant (maintenance therapy) in treating patients with multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stimulate the immune system to attack cancer cells. Giving ixazomib citrate and lenalidomide as maintenance therapy after transplant may prolong the length of time until the cancer returns.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlasma Cell Myeloma, Transplant-Related Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2, 2015
Enrollment StartDec 30, 2015
Primary CompletionJun 1, 2022
Study CompletionOct 24, 2025
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 10.6 years ago

Interventions

Ixazomib Citratedrug

Given PO

Laboratory Biomarker Analysisother

Correlative studies

Lenalidomidedrug

Given PO